Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In logistic regression, age, with EBV-positive NPC occurring at earlier age, and RASSF1, with RASSF1 hypermethylation being more frequent in EBV-positive NPC, remained significant.
|
28893862 |
2018 |
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
RASSF1A promoter methylation is a promising noninvasive biomarker for the diagnosis of NPC from tissue and brushing samples.
|
28396012 |
2017 |
Nasopharyngeal carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Hence, our study identified a strong association between RASSF1A methylation and NPC and highlighted a promising potential for RASSF1A methylation in NPC risk prediction of Chinese.
|
25824751 |
2015 |
Nasopharyngeal carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
This study reveals that CHK1-mediated phosphorylation of RASSF1A, at Serine 184, plays an important role in cell-cycle regulation and highlights that mutation of this CHK1 phosphorylation site in nasopharyngeal carcinoma has disease relevance.
|
24197116 |
2014 |
Nasopharyngeal carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Methylation of RASSF1A was more frequently detected in non-keratinizing NPC than in undifferentiated subtype (100% vs 66.7%; p=0.05).
|
22296674 |
2012 |
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A combination of RASSF1A and p16 gave good discrimination between NPC and non-NPC, but best results were combined analysis of five methylation markers (RASSF1A, p16, WIF1, CHFR and RIZ1) with detection rate of 98%.
|
21535891 |
2011 |
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
RASSF1A, which is frequently found inactivated in human cancers, is revealed as a tumor suppressor gene in nasopharyngeal carcinoma (NPC).
|
19450668 |
2009 |
Nasopharyngeal carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
The aim of this study was to investigate the expression profile and methylation status of RASSF1A gene, and to explore its concrete mechanisms as a tumor suppressor gene in Nasopharyngeal Carcinoma.
|
20042089 |
2009 |
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Several TSGs located at 3p21.3, such as RASSF1A, LTF and BLU, have been demonstrated to be involved in NPC development.
|
19129950 |
2009 |
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
By methylation-specific PCR, we analyzed the promoter methylation of three cancer-related genes: Ras Association domain Family 1A (RASSF1A), Death Associated Protein kinase (DAP-kinase) and Retinoic Acid Receptor beta2 (RARbeta2) in two NPC xenografts (C15 and C17), 68 primary NPC tumors, and nine normal nasopharyngeal epithelia.
|
19221469 |
2009 |
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
RASSF1A is a tumor-suppressor gene commonly inactivated in many types of human cancer including NPC.
|
17099724 |
2007 |
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we investigated the role of RASSF1A in the pathogenesis of esophageal squamous cell carcinoma (ESCC) and nasopharyngeal carcinoma (NPC).
|
17720308 |
2007 |
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study explores the methylation profile of RUNX3 in combination with p16, RASSF1A, CDH1 and hMLH1 in nasopharyngeal carcinoma (NPC) patients.
|
17201146 |
2007 |
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Strikingly, overexpression of Id2 is common in NPC and RASSF1A-induced repression of Id2 was mediated by the overexpression of activin betaE.
|
16116475 |
2006 |
Nasopharyngeal carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
A similarly high rate (74%) of promoter methylation of RASSF1A was also detected in the same group of NPC tissues, but no significant correlation between mutation and methylation was detected.
|
16096369 |
2005 |
Nasopharyngeal carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Our results suggest that aberrant hypermethylation of RASSF1A and high EBV load might be important events in NPC pathogenesis, and they may be useful molecular diagnostic markers for this cancer.
|
16229803 |
2005 |
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we aimed to investigate the expression and methylation status of RASSF4/AD037 and NORE1 in nasopharyngeal carcinoma (NPC) in which RASSF1A is frequently inactivated by promoter hypermethylation.
|
15375500 |
2004 |
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The contribution of RASSF1A in NPC tumorigenesis was investigated by restoring its expression in a RASSF1A deficient cell line, C666-1.
|
15027117 |
2004 |
Nasopharyngeal carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Although hypermethylation of RASSF1A, another TSG located immediately downstream of BLU, was detected in 20/27 (74%) of NPC tumors, no correlation between the hypermethylation of these two TSGs was observed (P=0.6334).
|
15122337 |
2004 |
Nasopharyngeal carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The methylation profile of NPC in order of frequency was CDH1 (50%), CDKN2B (50%), THBS1 (50%), RASSF1A (46%), MLH1 (40%), MGMT (28%), CDKN2A (23%), TP73 (20%), caspase-8 (7%), ARF (3%) and VHL (0%).
|
12632081 |
2003 |
Nasopharyngeal carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
The incidence of promoter methylation in NPC samples was 84% for RASSF1A, 80% for RARbeta2, 76% for DAP-kinase, 46% for p16, 17% for p15, 20% for p14, 20% for MGMT, and 3% for GSTP1.
|
11801549 |
2002 |
Nasopharyngeal carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The high incidence of RASSF1A alterations suggest that it is the critical target gene on chromosome 3p21.3 involved in the development of NPC.
|
11358799 |
2001 |